VBI Vaccines Inc VBIVQ

Healthcare Biotechnology

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

GREY:VBIVQ - Post by User

VBI Vaccines Inc

<< Previous

Bullboard Posts

Next >>

Post by buxtondudeon Jun 29, 2020 8:49am

400 Views

Post# 31202045

Can it reach it's target price of $8.00

that would be a nice profit, looking at covid vaccine related stock, nothing is impossible and VBIV is working with NRC on a vaccine, this could be potentially very explosive in term of stock price....

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”